Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma

Journal of Clinical Pathology

Volumn 64, Issue 6, 2011, Pages 498-503

  Xi, Hong Qing ^a   Zhao, Po ^a  

^a Chinese People's Liberation   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; EPHRIN RECEPTOR A3; KI 67 ANTIGEN;

ADULT; ARTICLE; CANCER INVASION; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BLOTTING, WESTERN; COLORECTAL NEOPLASMS; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM STAGING; PEPTIDES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR PROTEIN-TYROSINE KINASES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79956309778     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.087213     Document Type: Article

References (42)

1. Himanen JP, Nikolov DB. Eph receptors and ephrins. Int J Biochem Cell Biol 2003;35:130-4. (Pubitemid 35441270)
2. Wikkinson DG. Multiple roles of EPH receptors and ephrins in neural development. Nat Rev Neurosci 2001;2:155-64.
3. Anon. Unified nomenclature for Eph family receptors and their ligands, the ephrins. Eph Nomenclature Committee. Cell Growth Differ 1997;90:403-4.
4. Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science 2002;298:1912-34. (Pubitemid 35425239)
5. Wicks IP, Wilkinson D, Salvaris E, et al. Molecular cloning of HEK, the gene encoding a receptor tyrosine kinase expressed by human lymphoid tumor cell lines. Proc Natl Acad Sci USA 1992;89:1611-15.
6. Dottori M, Down M, Huttmann A, et al. Cloning and characterization of EphA3 (Hek) gene promoter: DNA methylation regulates expression in hematopoietic tumor cells. Blood 1999;94:2477-86. (Pubitemid 29467697)
7. Fox BP, Tabone CJ, Kandpal RP. Potential clinical relevance of Eph receptors and ephrin ligands expressed in prostate carcinoma cell lines. Biochem Biophys Res Commun 2006;342:1263-72.
8. Wimmer-Kleikamp SH, Lackmann M. Eph-modulated cell morphology, adhesion and motility in carcinogenesis. IUBMB life 2005;57:421-31. (Pubitemid 41073124)
9. Miraglia S, Godfrey W, Yin AH, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997;90:5013-21. (Pubitemid 28007218)
10. Mizrak D, Brittan M, Alison MR. CD133: molecule of the moment. J Pathol 2008;214:3-9.
11. O'Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodefcient mice. Nature 2007;445:106-10. (Pubitemid 46067310)
12. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-15. (Pubitemid 46067311)
13. Singh SK, Hawkins C, Clarke ID, et al. Identifcation of human brain tumor initiating cells. Nature 2004;432:396-401. (Pubitemid 39551674)
14. Miki J, Furusato B, Li H, et al. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 2007;67:3153-61. (Pubitemid 46724852)
15. Hilbe W, Dirnhofer S, Oberwasserlechner F, et al. CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol 2004;57:965-9. (Pubitemid 39208249)
16. Zhou L, Wei X, Cheng L, et al. CD133, One of the Markers of Cancer Stem Cells in Hep-2 Cell Line. Laryngoscope 2007;117:455-60.
17. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8. (Pubitemid 36418143)
18. Schrot RJ, Ma JH, Greco CM, et al. Organotypic distribution of stem cell markers in formalin-fixed brain harboring glioblastoma multiforme. J Neurooncol 2007;85:149-57. (Pubitemid 47629396)
19. Zhao P, Li Y, Lu Y. Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer 2010;20:218.
20. Horst D, Kriegl L, Engel J, et al. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008;99:1285-9.
21. Kojima M, Ishii G, Atsumi N, et al. Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci 2008;99:1578-83.
22. Compton CC. Colorectal carcinoma: diagnostic, prognostic, and molecular features. Mod Pathol 2003;16:376-88. (Pubitemid 36443987)
23. You WC, Jin F, Devesa S, et al. Rapid increase in colorectal cancer rates in urban Shanghai, 1972-97, in relation to dietary changes. J Cancer Epidemiol Prev 2002;7:143-6.
24. Hao XP, Willis JE, Pretlow TG, et al. Loss of fragile histidine triad epression in colorectal carcinomas and premalignant lesions. Cancer Res 2000;60:18-21. (Pubitemid 30058722)
25. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
26. Woolf SH. The best screening test for colorectal cancer - a personal choice. N Engl J Med 2000;343:1641-3. (Pubitemid 32162991)
27. Celis JE, Gromov P. Proteomics in translation cancer research: toward an integrated approach. Cancer Cell 2003;3:9-15. (Pubitemid 37448548)
28. Walsh JM, Terdiman JP. Colorectal cancer screening: scientific review. JAMA 2003;289:1288-96. (Pubitemid 37432910)
29. Bardelli A, Parsons DW, Silliman N, et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003;300:949. (Pubitemid 36548874)
30. Davies H, Hunter C, Smith R, et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005;65:7591-5. (Pubitemid 41297230)
31. Parsons DW, Wang TL, Samuels Y, et al. Colorectal cancer: mutations in a signalling pathway. Nature 2005;436:792. (Pubitemid 41160630)
32. Stephens P, Edkins S, Davies H, et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 2005;37:590-2. (Pubitemid 40770413)
33. Dodelet VC, Pasquale EB. Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene 2000;19:5614-19.
34. Clevers H, Batlle E. EphB/EphrinB receptors and Wnt signaling in colorectal cancer. Cancer Res 2006;66:2-5. (Pubitemid 43165998)
35. Smith LM, Walsh PT, Rudiger T, et al. EphA3 is induced by CD28 and IGF-1 and regulates cell adhesion. Exp Cell Res 2004;292:295-303. (Pubitemid 38018845)
36. Clifford N, Smith LM, Powell J, et al. The EphA3 receptor is expressed in a subset of rhabdomyosarcoma cell lines and suppresses cell adhesion and migration. J cell biochem 2008;105:1250-9.
37. Easty DJ, Herlyn M, Bennett DC. Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int J Cancer 1995;60:129-36.
38. Zelinski DP, Zantek ND, Stewart JC, et al. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001;61:2301-6. (Pubitemid 32692063)
39. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008;118:2111-20. (Pubitemid 351872330)
40. LaBarge MA, Bissell MJ. Is CD133 a marker of metastatic colon cancer stem cells? J Clin Invest 2008;118:2021-4.
41. Fluge Ø, Gravdal K, Carlsen E, et al. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Br J Cancer 2009;101:1282-9.
42. Ma YL, Peng JY, Zhang P, et al. Immunohistochemical analysis revealed CD34 and Ki67 protein expression as significant prognostic factors in colorectal cancer. Med Oncol 2010;27:304-9.